

## PROGRAM OBJECTIVE

The goal of the *PET Clinics* is to keep practicing radiologists and radiology residents up to date with current clinical practice in positron emission tomography by providing timely articles reviewing the state of the art in patient care.

## TARGET AUDIENCE

Practicing radiologists, radiology residents, and other health care professionals who provide patient care utilizing radiologic findings.

## LEARNING OBJECTIVES

Upon completion of this activity, participants will be able to:

1. Review origins, classifications, and clinical behaviors of neuroendocrine neoplasms.
2. Discuss most common neuroendocrine neoplasms, such as gastro-enteric-pancreatic neuroendocrine tumors, and identify current treatment options.
3. Recognize diagnostic modalities used to confirm, stage, assist in treatment, and assess therapy responses with neuroendocrine neoplasms.

## ACCREDITATION

The Elsevier Office of Continuing Medical Education (EOCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The EOCME designates this journal-based CME activity for a maximum of 11 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All other health care professionals requesting continuing education credit for this enduring material will be issued a certificate of participation.

## DISCLOSURE OF CONFLICTS OF INTEREST

The EOCME assesses conflict of interest with its instructors, faculty, planners, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by EOCME for fair balance, scientific objectivity, and patient care recommendations. EOCME is committed to providing its learners with CME activities that promote improvements or quality in healthcare and not a specific proprietary business or a commercial interest.

**The planning committee, staff, authors, and editors listed below have identified no financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interest related to the content of this CME activity:**

Chandrasekhar Bal, MD, DNB, DSc; Edward Barnett, BSc(Hons); Lisa Bodei, MD, PhD; Kunal Ramesh Chandekar, MD; Aniruddha Chatterjee, BSc, MSc, PhD; Dilara Denizmen; Heying Duan, MD; Amanda Henderson, BS; Andrei Iagaru, MD; Vetri Sudar Jayaprakasam, MBBS, FRCR, FEBNM; Lynette Jones, MSN, RN-BC; Asha Kandathil, MBBS, DMRD, MD; Wajahat Khatri, MD; Mohana Manoj Krishnamoorthy, Guobing Liu, MD, PhD; Charles Marcus, MD; Hyesun Park, MD; Chi Qi, PhD; Ajitha Ramesh, MBBS; Euan J. Rodger, BSc, MSc, PhD; Yasemin Sanli, MD; Swayamjeet Satapathy, MD; HuHongcheng Shi, MD, PhD; Jim Smith, MBChB, BMedSc (Hons); Ergi Spiro, BS; Rathana M. Subramaniam, MD, MPH, PhD, MBA, FRSN, FRANZCR, FACNM, FSNMMI, FAUR

**The planning committee, staff, authors, and editors listed below have identified financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interest related to the content of this CME activity:**

Steven P. Rowe, MD, PhD: Research funding and consulting: Progenics Pharmaceutical, Inc., Precision Molecular, Inc., PlenaryAI, Inc.; Ownership interest: Precision Molecular, Inc., PlenaryAI, Inc.

Lilja B. Solnes, MD, MBA: Research funding: Novartis AG Pharmaceutical Company, Cellectar, Inc., Precision Molecular, Inc.; Consultant: Progenics Pharmaceutical, Inc.

## UNAPPROVED/OFF-LABEL USE DISCLOSURE

The EOCME requires CME faculty to disclose to the participants:

1. When products or procedures being discussed are off-label, unlabelled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and
2. Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinions. Faculty may discuss information about pharmaceutical agents that is outside of FDA-approved labelling. This information is intended solely for CME and is not intended to promote off-label use of these medications. If you have any questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

**TO ENROLL**

To enroll in the *PET Clinics* Continuing Medical Education program, call customer service at 1-800-654-2452 or sign up online at <http://www.theclinics.com/home/cme>. The CME program is available to subscribers for an additional annual fee of USD 254.00.

**METHOD OF PARTICIPATION**

In order to claim credit, participants must complete the following:

1. Complete enrolment as indicated above.
2. Read the activity.
3. Complete the CME Test and Evaluation. Participants must achieve a score of 70% on the test. All CME Tests and Evaluations must be completed online.

**CME INQUIRIES/SPECIAL NEEDS**

For all CME inquiries or special needs, please contact [elsevierCME@elsevier.com](mailto:elsevierCME@elsevier.com).